LPA and congenital bilateral aplasia of vas deferens from CFTR mutation: These findings thus indicate that decreasing Lp(a) and/or blocking specific pathway(s) whereby this lipoprotein promotes CAVD could possibly translate into therapies in at-risk individuals.